Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stamm

Showing results (101-110 of 155) with videos related to

Pageof 16
Sort By:
Gastroenterology|February 1, 2017
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 InfectionEdward J Gane, Robert H Hyland, Yin Yang, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1988
A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteriaP B Fernandes, D T Chu, R N Swanson, et al.
Antiviral Therapy|October 25, 2017
Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitorEric Lawitz, Jenny C Yang, Luisa M Stamm, et al.
Gastroenterology|June 1, 2016
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 InfectionsEdward J Gane, Christian Schwabe, Robert H Hyland, et al.
Journal of Medical Virology|March 13, 2019
Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infectionRui Huang, Huiying Rao, Qing Xie, et al.
Neurology|January 30, 2015
Age of first exposure to football and later-life cognitive impairment in former NFL playersJulie M Stamm, Alexandra P Bourlas, Christine M Baugh, et al.
Hepatology (Baltimore, Md.)|February 22, 2017
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virusEric Lawitz, Fred Poordad, Jennifer Wells, et al.
The Journal of Experimental Medicine|November 5, 2003
Mycobacterium marinum escapes from phagosomes and is propelled by actin-based motilityLuisa M Stamm, J Hiroshi Morisaki, Lian-Yong Gao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 27, 2016
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/SofosbuvirCurtis Cooper, Susanna Naggie, Michael Saag, et al.
Journal of Viral Hepatitis|January 22, 2019
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment studyPeter Ruane, Simone I Strasser, Edward J Gane, et al.
Pageof 16

Showing results (101-110 of 155) with videos related to

Sort By:
Pageof 16
Gastroenterology|February 1, 2017
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 InfectionEdward J Gane, Robert H Hyland, Yin Yang, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1988
A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteriaP B Fernandes, D T Chu, R N Swanson, et al.
Antiviral Therapy|October 25, 2017
Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitorEric Lawitz, Jenny C Yang, Luisa M Stamm, et al.
Gastroenterology|June 1, 2016
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 InfectionsEdward J Gane, Christian Schwabe, Robert H Hyland, et al.
Journal of Medical Virology|March 13, 2019
Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infectionRui Huang, Huiying Rao, Qing Xie, et al.
Neurology|January 30, 2015
Age of first exposure to football and later-life cognitive impairment in former NFL playersJulie M Stamm, Alexandra P Bourlas, Christine M Baugh, et al.
Hepatology (Baltimore, Md.)|February 22, 2017
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virusEric Lawitz, Fred Poordad, Jennifer Wells, et al.
The Journal of Experimental Medicine|November 5, 2003
Mycobacterium marinum escapes from phagosomes and is propelled by actin-based motilityLuisa M Stamm, J Hiroshi Morisaki, Lian-Yong Gao, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 27, 2016
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/SofosbuvirCurtis Cooper, Susanna Naggie, Michael Saag, et al.
Journal of Viral Hepatitis|January 22, 2019
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment studyPeter Ruane, Simone I Strasser, Edward J Gane, et al.
Pageof 16